These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 6440792)

  • 1. Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers.
    Bialer M; Rubinstein A; Raz I; Abramsky O
    Eur J Clin Pharmacol; 1984; 27(4):501-3. PubMed ID: 6440792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of valpromide in dogs after various modes of administration.
    Bialer M; Rubinstein A
    Biopharm Drug Dispos; 1984; 5(2):177-83. PubMed ID: 6430363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bioavailability of a valproic acid preparation. The relative bioavailability of enteric-resistant valproic acid preparations in tablet form with simultaneously administered tetradeuterated valproic acid as the bioavailability reference].
    Hoffmann F; Jancik BC; von Unruh GE
    Arzneimittelforschung; 1986 Jul; 36(7):1118-22. PubMed ID: 3094548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans.
    Bialer M; Hussein Z; Dubrovsky J; Raz I; Abramsky O
    Isr J Med Sci; 1984 Jan; 20(1):46-9. PubMed ID: 6421770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
    Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
    Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of valproic acid after administration of three oral formulations in healthy adults.
    Bano G; Gupta S; Gupta KL; Raina RK
    J Assoc Physicians India; 1990 Sep; 38(9):629-30. PubMed ID: 2266076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-dose kinetics and bioavailability of sodium-hydrogen divalproate.
    Anderson P; Elwin CE
    Clin Neuropharmacol; 1985; 8(2):156-64. PubMed ID: 3924399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacology of valpromide.
    Bialer M
    Clin Pharmacokinet; 1991 Feb; 20(2):114-22. PubMed ID: 2029804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and bioavailability of sodium valproate.
    Klotz U; Antonin KH
    Clin Pharmacol Ther; 1977 Jun; 21(6):736-43. PubMed ID: 324695
    [No Abstract]   [Full Text] [Related]  

  • 10. Meal-dependent absorption of enteric-coated sodium valproate.
    Levy RH; Cenraud B; Loiseau P; Akbaraly R; Brachet-Liermain A; Guyot M; Gomeni R; Morselli PL
    Epilepsia; 1980 Jun; 21(3):273-80. PubMed ID: 6769666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacokinetic study of sodium di-n-propylacetate (usual tablet and enteric coated tablet with delayed absorption) (author's transl)].
    van de Mortel I; franck G
    Acta Neurol Belg; 1976; 76(3):165-72. PubMed ID: 788439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computerized model for evaluating the kinetics of in vitro release of valpromide from controlled-release tablets under nonsink conditions.
    Rubinstein A; Gonen A; Friedman M
    J Pharm Sci; 1986 Oct; 75(10):959-61. PubMed ID: 3098956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Some clinical pharmacological aspects of n-dipropylacetamide.
    Pisani F; Di Perri R
    Ital J Neurol Sci; 1980 Oct; 1(4):245-9. PubMed ID: 6802780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic evaluation of novel sustained-release dosage forms of valproic acid in humans.
    Bialer M; Friedman M; Dubrovsky J; Raz I; Abramsky O
    Biopharm Drug Dispos; 1985; 6(4):401-11. PubMed ID: 3936558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: in vitro/in vivo correlation.
    Kerr BM; Rettie AE; Eddy AC; Loiseau P; Guyot M; Wilensky AJ; Levy RH
    Clin Pharmacol Ther; 1989 Jul; 46(1):82-93. PubMed ID: 2501059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of enteric-coated valproic acid.
    Albright PS; Bruni J; Suria D
    Ther Drug Monit; 1984; 6(1):21-3. PubMed ID: 6424275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects.
    Bialer M; Haj-Yehia A; Barzaghi N; Pisani F; Perucca E
    Eur J Clin Pharmacol; 1990; 38(3):289-91. PubMed ID: 2111246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
    Wangemann M; Retzow A; Vens-Cappell B
    Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed toxicity following acute ingestion of valpromide.
    Payen C; Frantz P; Martin O; Parant F; Moulsma M; Pulce C; Descotes J
    Hum Exp Toxicol; 2004 Mar; 23(3):145-8. PubMed ID: 15119534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers.
    Dutta S; Reed RC; Cavanaugh JH
    J Clin Pharmacol; 2004 Jul; 44(7):737-42. PubMed ID: 15199078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.